Netflix has traded barbs with Comcast over the cable company's $40 billion takeover of Time Warner Cable.» Read More
Allergan may be more effective in its defense against a hostile takeover bid by Valeant Pharmaceuticals if it makes a purchase of its own, an analyst says.
CNBC's Simon Hobbs reports on all the market moving events in Europe today, including the possibility of GE buying turbine maker Alstom.
Emiliano Mellino, senior France correspondent at DealReporter, says that if an Alstom/GE deal was focused on the energy asset, it might be "easier to pull off."
Michael Yoshikami is no Apple fanboy but he thinks the company's innovation pipeline did not die with Steve Jobs and it's ridiculous to say otherwise.
Austan Goolsbee, 32 Advisors strategic partner, discusses whether U.S. tax policy is prompting the recent spate of M&A activity in big corporations.
Nicholas Heyman, William Blair, discusses General Electric's possible acquisition of French train and power plant builder Alstom for more than $13 billion.
Global business leaders eyeing expansion into India will be closely watching the outcome of the country’s general elections due to conclude on May 16.
The Fast Money traders share their final trades of the day.
The Fast Money traders offer up their best earth, wind, fire and water trades.
The Fast Money traders take a look at today's biggest market movers.
The U.S. antitrust approved of Facebook's acquisition of Oculus, a maker of virtual reality goggles. It is Facebook's third big acquisition.
CNBC's David Faber asks investor Carl Icahn if he succeeded in his eBay and Apple campaigns. Icahn also discuss his plans to seed other activist funds.
Bill Ackman also tells CNBC that Allergan's poison-pill defense doesn't make his takeover bid more difficult.
William Ackman, Pershing Square Capital Management, explains how his partnership with Valeant is structured. And J. Michael Pearson, Valeant chairman & CEO, discusses why he partnered with Ackman instead of pursing Allergan alone. Creating shareholder value is our job, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he is helping Valeant buy Allergan.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, weighs in on news that Allergan has adopted a "poison pill" defense strategy. Also Pearson shares his thoughts on adding some of Allergan's notable cosmetic products like Botox and Restasis to its growing arsenal.
J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.
William Ackman, Pershing Square Capital Management, explains why he decided to team up with Valeant Pharmaceuticals to make a play for Allergan.
Drugmakers eager to satisfy shareholders are wheeling, dealing, and in one case even making trades like a pro sports team looking to shake up its roster.
Comcast may divest about 4 million subscribers after its merger with Time Warner Cable and may sell a portion to Charter Communications.
Get the best of CNBC in your inbox
The U.S. energy renaissance has coincided with a stealthy boom in energy-related stocks.
Carlyle has raised $698 million for its dedicated Africa fund, nearly $200 million above its initial target.
CNBC.com Enterprise Reporter Lawrence Delevingne discusses how the private equity industry views Africa.